Thus, the small-molecule inhibitor (BMS309403) of FABP4 not only significantly reduced tumor load in syngeneic in situ mouse models but also increased cancer cell sensitivity to carboplatin both in vitro and in vivo. Here, FABP4 is linked to cancer.